The UK's NICE endorsed regular NHS funding for big-selling drugs from Roche and Sanofi, changing its mind in guidance for the multiple sclerosis and eczema drugs.
Everyone wants to find a cure for a debilitating long-term condition, but what can often be overlooked is the value in being able to first make life more manageable, comfortable or enjoyabl
The launch of Celgene’s multiple sclerosis drug, ozanimod, will be delayed after the company failed to submit key information in its application to the Food and Drug Administration (FDA).